Congestive heart failure has four stages, labeled A through D, under the system developed by the American College of Cardiology and American Heart Association (ACC/AHA). These stages track the structural progression of the disease, from risk factors alone to advanced heart failure. A separate but related system, the New York Heart Association (NYHA) functional classification, also uses four levels (Classes I through IV) to describe how much heart failure limits your daily activity. Doctors often use both systems together to get a complete picture.
The Four ACC/AHA Stages
The ACC/AHA staging system is built around a key idea: heart failure is progressive. Each stage represents a step forward in the disease, and under traditional guidelines, you don’t move backward. Once you’ve reached a given stage, your treatment plan reflects that permanent reality, even if your symptoms improve.
Stage A: At Risk
You have no symptoms and no structural changes to your heart, but you carry risk factors that make heart failure more likely. This includes high blood pressure, diabetes, coronary artery disease, obesity, a family history of cardiomyopathy, or a history of using drugs that can damage the heart. At this stage, the focus is entirely on prevention: keeping blood pressure below 130/80, staying physically active, maintaining a healthy weight, not smoking, and managing cholesterol. People with type 2 diabetes and existing cardiovascular disease may also be prescribed medication to reduce their risk of future heart failure hospitalization.
Five-year survival at Stage A is about 97%, which is nearly identical to people with no risk factors at all. That number underscores why this stage exists: catching and managing risk factors early can keep you from ever developing the disease.
Stage B: Structural Heart Disease, No Symptoms
Your heart has begun to change structurally, but you still feel fine. These changes might include a thickened heart wall, an enlarged chamber, reduced pumping function, or a history of heart attack. An echocardiogram or other imaging is typically what reveals the problem. The heart’s pumping efficiency, measured as ejection fraction, may range anywhere from mildly reduced (40% to 50%) to moderately or severely reduced (below 40%), all without you noticing any symptoms during normal activity.
Five-year survival is still high at 96%. Treatment at this stage focuses on slowing or stopping the structural damage from getting worse, often through blood pressure management and medications that reduce the heart’s workload.
Stage C: Symptomatic Heart Failure
This is where most people are when they receive a heart failure diagnosis. You have structural heart disease and you’ve developed symptoms: shortness of breath, fatigue, swelling in your legs or ankles, or difficulty exercising. These symptoms may come and go, and treatment can make you feel significantly better, but the underlying structural damage is considered permanent under the staging model.
The drop in prognosis at this stage is significant. Five-year survival falls to about 75%. Treatment becomes more intensive, combining multiple medications, dietary changes (particularly sodium restriction), and close monitoring. One important nuance from recent research: some patients with potentially reversible conditions may achieve enough improvement to enter what some cardiologists call “remission,” functioning more like Stage B. This is a newer concept and doesn’t apply to everyone, but it reflects growing optimism that aggressive treatment can sometimes partially reverse course.
Stage D: Advanced Heart Failure
Stage D means symptoms persist despite maximum medical treatment. Everyday activities become extremely difficult or impossible, and hospitalizations become frequent. Five-year survival drops to roughly 20%.
At this point, the conversation shifts to advanced options. These may include a ventricular assist device (a mechanical pump surgically implanted to help the heart), heart transplant evaluation, or continuous IV medications to support heart function. For patients whose overall health has declined too far for surgical options, palliative care becomes central, focusing on managing symptoms, clarifying goals, supporting caregivers, and maintaining the best possible quality of life.
The Four NYHA Functional Classes
While the ACC/AHA stages describe where you are in the disease’s progression, the NYHA system describes how you feel day to day. It has four classes:
- Class I: No limitation. Ordinary physical activity doesn’t cause fatigue, shortness of breath, or heart palpitations.
- Class II: Slight limitation. You’re comfortable at rest, but ordinary activity like climbing stairs or carrying groceries causes fatigue, shortness of breath, or chest discomfort.
- Class III: Marked limitation. You’re comfortable at rest, but even light activity, less than what most people would consider ordinary, triggers symptoms.
- Class IV: Symptoms at rest. Any physical activity makes them worse.
The critical difference is that NYHA class can change. A good medication adjustment might move you from Class III to Class II. A bad infection or missed doses might push you from Class II to Class III. The ACC/AHA stage, by contrast, is designed as a one-way system. You can feel better, but the stage generally doesn’t reset.
How the Two Systems Work Together
Doctors use both systems because they answer different questions. The ACC/AHA stage tells your care team where you are in the overall arc of heart failure and what treatments are appropriate. The NYHA class tells them how well those treatments are working right now and how much the disease is affecting your life on a given day.
For example, a patient in ACC/AHA Stage C (structural damage with symptoms) might be NYHA Class I on a good treatment regimen, meaning they feel essentially normal during daily activities. That same patient during a flare could shift to NYHA Class III without their ACC/AHA stage changing. Both pieces of information matter: the stage guides long-term strategy, and the class captures real-time function.
Screening and Early Detection
A simple blood test measuring a protein called NT-proBNP can help identify heart failure before symptoms become obvious. Normal levels are generally below 125 pg/mL for adults under 75, and below 450 pg/mL for those over 75. Levels above 900 pg/mL suggest heart failure. The 2022 AHA/ACC guidelines recommend screening high-risk patients with this blood test, because catching elevated levels early and starting treatment can reduce the likelihood of progressing to symptomatic heart failure.
This is especially relevant for people in Stage A or Stage B, where the disease is silent. If you have diabetes, long-standing high blood pressure, or a previous heart attack, this blood test can reveal whether your heart is under more stress than you realize.